Galapagos (GLPG) said that its investigational CD19 CAR T-cell therapy, GLPG5101, has demonstrated "encouraging safety outcomes" in patients with relapsed non-Hodgkin's lymphoma, including low rates of high-grade toxicities.
Of the 64 patients enrolled, 95% received fresh, non-cryopreserved GLPG5101 without requiring cytotoxic bridging therapy, findings from the phase 1/2 study showed, Galapagos said Thursday in a statement.
Galapagos plans to present the data at the 30th European Hematology Association Congress.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.